Wan Song, Shukla Nilima, Yim Anthony P C, Johnson Jason L, Angelini Gianni D, Jeremy Jamie Y
Department of Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China.
J Thorac Cardiovasc Surg. 2007 Feb;133(2):494-500. doi: 10.1016/j.jtcvs.2006.08.071.
In patients who have undergone coronary artery bypass grafting, blood copper levels are elevated for 6 weeks after surgery. Copper is an established risk factor for cardiovascular disease and atherogenesis and promotes oxidative stress, lipid oxidation, cell proliferation, and matrix formation, all components of vein graft disease. This project therefore examined the effect of the copper chelator penicillamine on saphenous vein graft thickening in a pig model.
Saphenous vein-carotid artery interposition grafts were carried out in Landrace pigs. Penicillamine (10 mg/kg once daily, n = 8) was administered orally incorporated into small amounts of mashed potato for 1 month (n = 8 controls). Vein grafts were then excised and fixed at 100 mm Hg, histologic sections were prepared, and morphometry and measurement of proliferating cell nuclear antigen count were carried out. In vitro studies on the effect of copper or penicillamine on human vascular smooth muscle cell replication was carried out with bromodeoxyuridine incorporation.
Administration of penicillamine had a potent inhibitory effect on both neointimal and medial thickness and proliferating cell nuclear antigen count but elicited a marked increase in luminal area and reduced serum copper concentrations. In vitro, copper augmented vascular smooth muscle cell proliferation, an effect blocked by penicillamine. Penicillamine alone also inhibited in vitro vascular smooth muscle cell replication.
The administration of penicillamine reduces vein graft thickening and promotes positive remodeling through negation of copper-induced cell proliferation. Copper chelators may therefore be therapeutically useful in preventing late vein graft failure in patients undergoing reconstructive arterial surgery.
在接受冠状动脉搭桥术的患者中,术后6周血铜水平会升高。铜是心血管疾病和动脉粥样硬化形成的既定危险因素,会促进氧化应激、脂质氧化、细胞增殖和基质形成,而这些都是静脉移植物疾病的组成部分。因此,本项目研究了铜螯合剂青霉胺对猪模型中隐静脉移植物增厚的影响。
在长白猪身上进行隐静脉-颈动脉间置移植。将青霉胺(10毫克/千克,每日一次,n = 8)混入少量土豆泥中口服给药1个月(n = 8为对照组)。然后切除静脉移植物并在100毫米汞柱压力下固定,制备组织学切片,并进行形态计量学分析和增殖细胞核抗原计数测量。采用溴脱氧尿苷掺入法对铜或青霉胺对人血管平滑肌细胞复制的影响进行体外研究。
给予青霉胺对新生内膜和中膜厚度以及增殖细胞核抗原计数均有显著抑制作用,但管腔面积显著增加,血清铜浓度降低。在体外,铜可增强血管平滑肌细胞增殖,而青霉胺可阻断这一作用。单独使用青霉胺也可抑制体外血管平滑肌细胞复制。
给予青霉胺可减少静脉移植物增厚,并通过抑制铜诱导的细胞增殖促进正向重塑。因此,铜螯合剂可能在预防接受重建性动脉手术患者的晚期静脉移植物失败方面具有治疗作用。